Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts [Seeking Alpha]
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: Seeking Alpha
The company focuses on T-cell therapies for solid tumors and has two clinical-stage assets. Lyell has upcoming data catalysts, with Phase 1 results expected in the first half of 2024 and the second half of this year. The two programs in question involve a CAR-T cell therapy targeting breast and lung cancer and a TIL therapy targeting melanoma, lung, and colorectal cancer. Lyell has funding to last until 2027 and a review of its approach to designing cell therapies gives me some optimism upcoming data readouts can be positive - there is substantial risk to this thesis; however, that must be acknowledged. Investment Overview Lyell Immunopharma, Inc.'s NASDAQ: LYEL ) stock price has risen by 20% year to date and 45% across the past 12 months. The stock has been moderately volatile, reaching highs of $3 in early March, and at the end of last week, before dropping this Recommended For You Recommended For You About LYEL Stock Related Stocks Trending Analysis Trending
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Outpace Bio Announces Multiple Presentations at the 2024 American Association of Cancer Research (AACR) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- 2seventy bio appoints Eli Casdin and Charles Newton to its board of directors [Seeking Alpha]Seeking Alpha
- CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returns [Yahoo! Finance]Yahoo! Finance
- Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know [Yahoo! Finance]Yahoo! Finance
LYEL
Sec Filings
- 4/22/24 - Form ARS
- 4/22/24 - Form DEFA14A
- 4/22/24 - Form DEF
- LYEL's page on the SEC website